Deuterocelexin is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

LuciDeucra

Please use under the guidance of a physician

Product Name: LuciDeucra

Manufacturer: Lucius Pharmaceuticals (Laos) Co., Ltd.

Chinese name: Deuterated colexitinib tablets

English name: Deucravacitinib tablets

Drug approval number: 06 L 1111/24

【Indications】

LuciDeucra is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Restrictions on Use:

It is not recommended to be used in combination with other potent immunosuppressants.

【Usage and Dosage】

• For evaluation of LuciDeucra prior to use, please refer to the full instructions.

•The recommended dose is 6 mg orally once daily, either on an empty stomach or with a meal.

【Specification】

6mg/tablet, 30 tablets/box.

【Contraindications】

Do not use if you have an allergic reaction to deuterated lecitinib or other ingredients.

【Warnings and precautions】

• Hypersensitivity reactions: Hypersensitivity reactions such as angioedema have been reported. If clinically significant hypersensitivity reactions occur, discontinue use.

•Infections: LuciDeucra may increase the risk of infection. Avoid use in patients with active or severe infections. If a severe infection develops, discontinue LuciDeucra until the infection resolves.

•Tuberculosis: Assess for tuberculosis prior to initiating treatment with LuciDeucra.

•Malignancies: Malignancies including lymphoma have been observed in clinical trials with LuciDeucra (deucravacitinib).

•Rhabdomyolysis and elevated CPK.

• Laboratory Abnormalities: Evaluate serum triglycerides periodically. Evaluate liver enzymes at baseline and thereafter in patients with known or suspected liver disease.

•Immunizations: Avoid use with live vaccines.

• Potential risks associated with JAK inhibition: It is unknown whether TYK2 inhibition is associated with observed or potential adverse reactions to JAK inhibition. In patients with rheumatoid arthritis (RA), all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, total thrombosis, deep vein thrombosis, pulmonary embolism, and malignancies (excluding non-skin cancers) was higher in patients treated with JAK inhibitors compared with those treated with TNF blockers. LuciDeucra is not approved for use in RA.

【Adverse Reactions】

The most common adverse reactions (≥1%) were upper respiratory tract infection, increased blood creatine phosphokinase, herpes simplex, oral ulcers, folliculitis, and acne.

【Use by specific groups】

LuciDeucra is not recommended in patients with severe hepatic impairment (Child-Pugh C).

【Storage】

Storage temperature is 20℃ to 25℃ (68℉ to 77℉), short-distance transportation is allowed between 15℃ to 30℃ (59℉ to 86℉). Protect from moisture.